Kostas Biliouris Analyst PerformanceManaging Director at OppenheimerKostas Biliouris is a stock analyst at Oppenheimer focused in the medical sector, covering 17 publicly traded companies. Over the past year, Kostas Biliouris has issued 16 stock ratings, including buy and hold recommendations. While full access to Kostas Biliouris' proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Kostas Biliouris' coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions. Analyst Rankings, Coverage, and Performance StatisticsAnalyst RankingSubscribe to MarketBeat All Access for the analyst's recommendation accuracy rating MarketBeatAverage Return00.00% 12-Month ROISuccess Rate00.00% Profitable RatingsTotal Ratings23 Last 3 YearsBuy Recommendations69.57% 16 Buy RatingsCompanies Covered17 Unique Companies Ratings Distribution23RatingsDistribution of strong buy, buy, hold, and sell ratings by Kostas Biliouris.RatingPercentageCount Strong Buy0.0%0 ratings Buy69.6%16 ratings Hold30.4%7 ratings Sell0.0%0 ratingsOut of 23 total stock ratings issued by Kostas Biliouris at Oppenheimer, the majority (69.6%) have been Buy recommendations, followed by 30.4% Hold.Best & Worst CallsBest Call000.0%DYNMar 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Worst Call000.0%RNAMar 2025Subscribe to MarketBeat All Access to get analyst recommendation ROI.Exchange CoverageExchangePercentageCountNASDAQ100.0% of companies on NASDAQ17 companiesKostas Biliouris, an analyst at Oppenheimer, currently covers 17 companies listed on , with the majority traded on NASDAQ.Coverage FocusSector IconSectorPercentageMedical16 companies94.1%Manufacturing1 company5.9%Kostas Biliouris of Oppenheimer specializes in stock coverage within the Medical sector, with additional focus on Manufacturing companies.Coverage IndustriesIndustryPercentageMED - BIOMED/GENE10 companies58.8%MED - DRUGS6 companies35.3%BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES1 company5.9% Kostas Biliouris' Ratings History at Oppenheimer Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 4 Years 5 Years All Time Timeframe Start Date End Date All Ratings Strong Buy Buy Hold Sell Rating Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.Available with a MarketBeat All Access Subscription12-Month ROIUpgrade to All Access to use the All ROI Filter Export CompanyReport DateActionReport Date Price12-MonthPrice TargetRating12-MonthPrice & ROIDetailsDSGNDesign Therapeutics5/4/2026Boost Price Target$13.30$21.00Outperform$0.0000.00% ROISRPTSarepta Therapeutics3/19/2026Reiterated Rating$17.04$37.00Outperform$0.0000.00% ROIPRMEPrime Medicine3/12/2026Initiated Coverage$3.83$11.00Outperform$0.0000.00% ROIPEPGPepGen2/25/2026Initiated Coverage$6.49$15.00Outperform$0.0000.00% ROITRDAEntrada Therapeutics1/28/2026Initiated Coverage$11.00$21.00Outperform$0.0000.00% ROICNTACentessa Pharmaceuticals12/10/2025Boost Price Target$28.60$62.00Outperform$0.0000.00% ROISRPTSarepta Therapeutics9/22/2025Upgrade$17.43$50.00Outperform$0.0000.00% ROITRMLTourmaline Bio9/15/2025Downgrade$47.61$48.00Market Perform$0.0000.00% ROIALNYAlnylam Pharmaceuticals9/5/2025Boost Price Target$453.40$470.00Outperform$0.0000.00% ROIIONSIonis Pharmaceuticals9/3/2025Upgrade$57.49$70.00Outperform$0.0000.00% ROISRPTSarepta Therapeutics7/29/2025Boost Price Target$16.75$50.00Market Perform$0.0000.00% ROISRPTSarepta Therapeutics7/21/2025Lower Price Target$14.07$50.00Market Perform$0.0000.00% ROIJSPRJasper Therapeutics7/8/2025Reiterated Rating$3.04Market Perform$0.0000.00% ROIVERVVerve Therapeutics6/27/2025Reiterated Rating$11.29$13.50Market Perform$0.0000.00% ROIALNYAlnylam Pharmaceuticals6/24/2025Boost Price Target$323.26$360.00Outperform$0.0000.00% ROISRPTSarepta Therapeutics6/16/2025Downgrade$36.18$70.00Market Perform$0.0000.00% ROIRNAAvidity Biosciences3/12/2025Initiated Coverage$29.58$72.00Outperform$00.0000.00% ROIDYNDyne Therapeutics3/12/2025Initiated Coverage$12.03$50.00Outperform$00.0000.00% ROIRCKTRocket Pharmaceuticals3/12/2025Initiated Coverage$8.21$50.00Outperform$0.0000.00% ROISLNSilence Therapeutics3/4/2025Lower Price Target$4.56$25.00Outperform$0.0000.00% ROIIONSIonis Pharmaceuticals2/20/2025Lower Price Target$31.29$45.00Market Perform$00.0000.00% ROINTLAIntellia Therapeutics1/10/2025Lower Price Target$11.50$50.00Outperform$00.0000.00% ROI Stock Forecasts and Research Tools Today's Analyst Ratings U.S. Ratings U.K. Ratings Canadian Ratings All Upgrades All Downgrades All Initiations All Price Target Changes Top-Rated Stocks Top Rated Stocks Top-Rated Dividend Stocks Top-Rated Small-Cap Stocks Top-Rated Tech Stocks Most-Upgraded Stocks Most-Downgraded Stocks Lowest-Rated Stocks More Ratings Tools Stock Ratings by Issuer Top-Rated Analysts Top-Rated Brokerages Stock Ratings Screener Free Ratings Newsletter Price Forecasts for Popular Stocks Alphabet (Google) Stock ForecastAmazon Stock ForecastApple Stock ForecastMeta (Facebook) Stock ForecastMicrosoft Stock ForecastNetflix Stock ForecastNvidia Stock ForecastTesla Stock Forecast Top Stock Recommendations by BrokerageWall Street ZenUBS GroupCitigroupBarclaysMorgan StanleyWells Fargo & CompanyRoyal Bank Of CanadaJPMorgan Chase & Co.Jefferies Financial GroupThe Goldman Sachs GroupTruist FinancialTD CowenPiper SandlerRaymond James FinancialStifel Nicolaus Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
